Did Beta Bionics beat or miss consensus estimates last quarter?

What is Beta Bionics's gross profit margin?

What factors drove the changes in Beta Bionics's revenue and profit?

What were the key takeaways from Beta Bionics's earnings call?

What does Beta Bionics do and what are its main business segments?

What were the key takeaways from Beta Bionics’s earnings call?

What is the market's earnings forecast for Beta Bionics next quarter?

What is the revenue and EPS growth rate for Beta Bionics year over year?

- **Revenue Surges 63% YoY**: Q3 2025 sales of $27.3M driven by 5,334 new patient starts, 30% via pharmacy channel (vs. 8% in Q3 2024).
- **Gross Margin at 55.5%**: Expansion due to scale, high-margin pharmacy revenue, and cost control. Full-year guidance raised to >$96.5M.
- **Pipeline Momentum**: Mint patch pump on track for 2027 launch; bihormonal system feasibility trial begins Q4 2025.
- **FDA Compliance**: Remediation of Form 483 complete; temporary increase in MAUDE filings due to new reporting criteria.
- **Cash Strength**: $274M in cash, supporting growth and free cash flow generation.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 net sales of $27.3 million, up 63% YoY, driven by 5,334 new patient starts (68% YoY growth). Pharmacy channel accounted for 30% of new starts, up from 8% in Q3 2024.
- **Gross Margin Expansion**: 55.5% gross margin (vs. 53.4% Q3 2024), driven by scale, high-margin pharmacy revenue, and cost discipline. Q4 gross margin expected to remain stable or improve slightly.
- **Pipeline Updates**: Mint patch pump on track for 2027 launch; bihormonal system feasibility trial to begin Q4 2025. Recent FDA clearance for iLet usability enhancements.
- **Regulatory Update**: Remediation of FDA Form 483 observation complete; new complaint reporting criteria may increase MAUDE filings temporarily.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP net income $420M; Non-GAAP EPS $1.08 (vs. $0.95 prior guidance). Operating expenses $32.2M (62% YoY growth) due to sales team expansion and R&D investments.
- **Cash Position**: $274M in cash, supporting initiatives and free cash flow generation.
- **Updated Guidance**: Full-year 2025 revenue >$96.5M (vs. $88-93M prior). Gross margin 54-55% (vs. 52-55% prior). Q4 revenue ~$28.5M, with pharmacy mix ~30% of new starts.
- **Risk Consideration**: Tariff impacts on gross margin remain under review, but no immediate threats identified.

**【Q&A Key Highlights】**
- **Demand Drivers**: 70% of new patients from MDI converts, 30% from competitive pumps. Consistent across quarters, reflecting market penetration strategy.
- **Mint Launch**: 510(k) clearance and manufacturing readiness on track for 2027 launch. No delays expected from government shutdown.
- **FDA Complaints**: Increased MAUDE filings due to new reporting criteria, not indicative of product issues. Remediation complete by Q2 2026.
- **Type 2 Diabetes**: 25% of Q3 new starts in type 2 diabetes; no timeline for FDA indication, but off-label use continues.
- **Competitive Landscape**: Differentiated iLet user experience and pharmacy channel adoption maintain competitive edge.


Beta Bionics, Inc. (BBNX) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 net sales up 54% YoY to $23.2 million, driven by 37% YoY new patient starts
- **Channel Shift**: Pharmacy channel adoption accelerates to 20%+ of new patient starts (vs. mid-single digits in Q2 2024)
- **Guidance Raise**: Full year 2025 net sales raised to $88-93 million (midpoint +$3 million)
- **CMS Impact**: Potential shift to pay-as-you-go model for Medicare fee-for-service could create long-term tailwind
- **Pipeline Progress**: Mint patch pump on track for Q4 2027 launch, bihormonal system PK/PD results supportive of development
- **Financial Strength**: $281 million cash balance, gross margin expanded to 53.8% despite pharmacy channel headwinds

**【CEO Summary Section】**
- Q2 2025 net sales: $23.2 million (54% YoY growth)
- New patient starts: 4,934 (37% YoY growth)
- Pharmacy channel adoption: 20%+ of new patient starts (vs. mid-single digits in Q2 2024)
- Gross margin: 53.8% (stable vs. Q2 2024)
- Key product launches: Abbott Libre 3 Plus integration, Color iLet, Bionic Circle app
- CMS 2026 DME proposal: Potential shift to pay-as-you-go model for Medicare fee-for-service
- Innovation pipeline updates: Mint patch pump (target Q4 2027 launch), bihormonal system PK/PD study results
- Type 2 diabetes off-label use: 25% of new patient starts in Q2

**【CFO Financial Commentary】**
- Full year 2025 guidance raised to $88-93 million (vs. prior $82-87 million)
- Gross margin updated to 52-55% (vs. prior 50-53%)
- Operating expenses: $32.4 million (63% YoY growth)
- Cash position: $281 million
- Pharmacy channel tailwind: 7x larger installed base vs. Q2 2024
- Manufacturing leverage: Lower per-unit costs

**【Q&A Highlights】**
- Pharmacy ASP dynamics: Rebate-driven decline in pump pricing
- Churn rate: Not disclosed, but prioritized as most profitable channel
- CMS proposal timing: Final rule expected Q4 2025, implementation 2027+ 
- Sales force expansion: 63 territories as of Q2, no further hires in 2025
- Type 2 diabetes strategy: No specific timeline for label expansion
- Recurring revenue visibility: Growing pharmacy installed base drives predictability

Beta Bionics (BBNX)-29 Jul 25-2025 Q2 Earnings call transcript

- **Revenue and Patient Growth**: Q1 2025 net sales up 36% YoY to $17.6M, with 48% YoY increase in new patient starts to 3,853.
- **Pharmacy Channel Momentum**: 22-25% of new starts via pharmacy in 2025 (vs. prior >20%), with $8M+ cumulative revenue tailwind by 2028.
- **Gross Margin Outlook**: 50-53% for 2025, despite near-term headwinds from pharmacy expansion.
- **Innovation Pipeline**: Patch pump on track for 2027 launch, bi-hormonal pump PK/PD study underway, and 20%+ type 2 diabetes patient adoption.
- **Cash Position**: $295.5M in cash to support growth and free cash flow generation.

**【CEO Summary Section】**
- Q1 2025 net sales reached $17.6 million, up 36% YoY, driven by 3,853 new patient starts (+48% YoY). Low 20s% of new starts were reimbursed via pharmacy, exceeding prior guidance of >20%.
- Gross margin declined to 50.9% (vs. 55.7% Q1 2024) due to higher pharmacy adoption, but management expects medium-term margin expansion via pay-as-you-go model.
- Innovation pipeline progress: patch pump targeting 2027 launch, bi-hormonal pump PK/PD study underway, and 20%+ Q1 type 2 diabetes patient starts.

**【CFO Financial Commentary】**
- Operating expenses rose 66% YoY to $27.6 million, driven by field sales expansion and public company costs.
- Cash reserves of $295.5 million support free cash flow generation expectations.
- Updated 2025 guidance: $82-87 million net sales (vs. prior $80-85M), 22-25% pharmacy new starts (vs. >20%), and 50-53% gross margin (vs. prior ≥50%).
- Pharmacy channel headwind of ~$1M in 2025 is offset by $8M+ cumulative tailwind through 2028.

**【Q&A Key Takeaways】**
- Pharmacy adoption success: Prime PBM health plans exceeded expectations, with Q1 2025 pharmacy mix >20% (vs. mid-single digits Q1 2024).
- Sales force expansion: 63 territories (up 20 in Q1) driving sequential new patient starts growth, with immediate Q2 contribution.
- Competition: iLet's adaptive algorithm and real-world outcomes differentiate from traditional pumps.
- Patient retention: Pharmacy model lowers out-of-pocket costs, improving adherence and lifetime value.
- Bi-hormonal pump: Pivotal trials planned for 2025, targeting 505(b)(2) NDA submission.

BBNX

BBNX fundamentals

Earnings Call

You can ask Aime